Castle Biosciences Inc (NAS:CSTL)
$ 24.37 0.63 (2.65%) Market Cap: 672.79 Mil Enterprise Value: 458.63 Mil PE Ratio: 0 PB Ratio: 1.67 GF Score: 79/100

Castle Biosciences Inc To Host 2022 Investor Day Transcript

Sep 20, 2022 / 08:00PM GMT
Release Date Price: $26.51 (+2.71%)
Frank Stokes
Castle Biosciences, Inc. - CFO & Treasurer

(presentation)

Frank Stokes
Castle Biosciences, Inc. - CFO & Treasurer

Thank you all for joining us today for Castle's 2022 Investor Day.

Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. So please take a moment to review these statements.

We'll start today by hearing from Derek Maetzold, Castle's Founder, President and CEO, and he'll discuss our overall corporate strategy. Then Dr. Brent Moody of Heritage Medical Associates, a thought leader in dermatology and Mohs surgeon will then discuss 2 of our skin cancer tests focused on risk stratification, DecisionDx-Melanoma and DecisionDx-SCC. We'll then have Dr. Matt Goldberg, dermatologist, dermatopathologist and our head Medical Director, discuss our diagnostic GEP offering, myPath Melanoma and DiffDx-melanoma. He will then give an overview of our inflammatory skin disease pipeline

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot